MolecularMD was founded to address the critical needs of chronic myelogenous leukemia (CML) patients. Investigators at Oregon Health Science University (OHSU) revealed that these patients often develop a wide range of genetic aberrations during the progression of their disease. Because of this, they require accurate and reliable molecular diagnosis to determine the recommended therapeutic course of action. Moreover, highly accurate and reproducible molecular monitoring of residual disease in CML patients is critical for reliable assessment of current therapy efficacy.

Based on the translational medicine accomplishments of Drs. Brian Druker and Michael Heinrich of OHSU, our efforts are geared toward improving cancer patient survival by linking molecular response to effective molecular cancer therapy. As such, we provide testing services for the clinical development of targeted cancer therapies. Our ultimate goal is to become the leader in targeted molecular assays for oncodiagnostics and, eventually, for all of personalized medicine.

MolecularMD scientific founders have over 30 years of combined experience in CML research and have developed sensitive and highly reliable molecular assays for leukemias, lymphomas, and solid tumors. Our management team has over 40 years of experience in the life sciences and is well-versed at meeting the needs of pharmaceutical drug development customers.